XWELL (NASDAQ:XWEL) reported quarterly sales of $10.70 million which missed the analyst consensus estimate of $14.37 million by 25.54 percent. This is a 60.03 percent decrease over sales of $26.77 million the same period last year.
Mirum Pharmaceuticals’ LIVMARLI Receives Reimbursement Recommendation By Canada’s CADTH For Patients With Cholestatic Pruritus In Alagille Syndrome
- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder- LIVMARLI is the first and only approved medication to
